On antibiotic consumption with bacterial resistance: The example of quinolone-resistant Escherichia coli;De la consommation d'antibiotiques aux résistances bactériennes: L'exemple de la résistance d'Escherichia coli aux quinolones

Medecine Therapeutique

Volumn 17, Issue 4, 2011, Pages 294-301

  Batard, Eric ^a,b   Montassier, Emmanuel ^a,b   Ballereau, Françoise ^c   Potel, Gilles ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CHU DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855486003     PISSN: 12646520     EISSN: 19524099     Source Type: Journal    
DOI: 10.1684/met.2011.0341     Document Type: Review

References (39)

1. HAS. Stratégie d'antibiothérapie et prévention des résistances bactériennes en établissement de santé. 2008: http://www.hassante.fr/portail/jcms/c-665169/strategie-d-antibiotherapie- etprevention-des-resistances-bacteriennes-en-etablissement-de-sante.
2. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77. (Pubitemid 46084814)
3. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38 Suppl 4: S341-5. (Pubitemid 38669889)
4. Hooper DC. Quinolones. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. Philadelphia: Elsevier Churchill Livingstone; 2005:451-73.
5. AFSSAPS. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires chez l'adulte. Recommandations. 2008: http://www.infectiologie.com/site/medias/-documents/consensus/ afssaps-inf-urinaires-adulte-recos.pdf.
6. ONERBA. Rapport d'activité 2008. Paris: ONERBA; 2010: http://www.onerba.org/spip. php?article92.
7. Thibaut S, Caillon J, Huart C, et al. Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004-2007). Med Mal Infect 2010;40:74-80.
8. ECDC. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2010: http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC-DispForm.aspx?ID= 580.
9. ESAC. ESAC Yearbook 2009. European Surveillance of Antimicrobial Consumption; 2010: http://www.esac.ua.ac.be/main.aspx?c=*ESAC2&n= 50036.
10. AFSSAPS. Dix ans d'évolution des consommations d'antibiotiques en France. 2011: http://www.afssaps.fr/var/afssaps-site/storage/original/ application/263354f238b8f7061cdb52319655ca07.pdf.
11. Sabuncu E, David J, Bernede-Bauduin C, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009;6:e1000084.
12. Dumartin C, L'Heriteau F, Pefau M, et al. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother 2010;65:2028-36.
13. Doco-Lecompte T, Demore B, Burty C, et al. Relevance of fluoroquinolone use in Lorraine: results of the first survey. Med Mal Infect 2010;40:106-11.
14. Moisan-Colliard C. Bactériémies à Escherichia coli. Etude prospective sur 184 cas au CHU de Nantes. Thèse. Université de Nantes; 2005, http://archive.bu.univ-nantes.fr/pollux/show.action?id= b366c1bb-6f9c-4e86-981f-99530635eb8b.
15. Donaldson AD, Barkham T. De-escalation for amoxicillinsusceptible Escherichia coli: easier said than done. J Hosp Infect 2010;74:304-5.
16. Moulin G, Cavalie P, Pellanne I, et al. A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005. J Antimicrob Chemother 2008;62:617-25.
17. Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization ranking of antimicrobials according to their importance in human medicine: A critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clin Infect Dis 2009;49:132-41.
18. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobia usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003;52:1005-10. (Pubitemid 38008423)
19. Vernaz N, Huttner B, Muscionico D, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011;66:928-35.
20. Kiffer CR, Camargo EC, Shimakura SE, et al. A spatial approach for the epidemiology of antibiotic use and resistance in communitybased studies: the emergence of urban clusters of Escherichia coli quinolone resistance in Sao Paulo, Brasil. Int J Health Geogr 2011;10:17.
21. Vellinga A, Murphy AW, Hanahoe B, Bennett K, Cormican M. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother 2010;65:1514-20.
22. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14:1722-30.
23. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435-40. (Pubitemid 41099634)
24. Gallini A, Degris E, Desplas M, et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010;65:2650-7.
25. Bergman M, Nyberg ST, Huovinen P, Paakkari P, Hakanen AJ. Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother 2009;53:912-7.
26. Ruyer O, Slekovec C, Bertrand X, et al. Impact of regional guideines on the management of urinary tract infections with antibiotics. Med Mal Infect 2010;40:352-7.
27. Gendrin V, Letranchant L, Henard S, et al. Impact of corrective measures on fluoroquinolones prescriptions for urinary tract infections during a 2-round relevance study. Presse Med 2011;
28. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006;42:778-84. (Pubitemid 43363932)
29. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isoated from urine by culture in a community setting. Clin Infect Dis 2009;49:869-75.
30. Willemsen I, Cooper B, van Buitenen C, Winters M, Andriesse G, Kluytmans J. Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. Antimicrob Agents Chemother 2010;54:3763-9.
31. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
32. SPILF-AFSSAPS. Antibiothérapie par voie générale dans les infections respiratoires basses de l'adulte. Pneumonie aiguë communautaire. Exacerbations de Bronchopneumopathie Chronique Obstructive. Mise au point. 2010: http://www.afssaps.fr/var/afssaps-site/storage/original/ application/b33b6936699f3fefdd075316c40a0734.pdf.
33. AFSSAPS. Traitement antibiotique de la légionellose chez l'adulte. Actualisation. 2011: http://www.afssaps.fr/var/afssaps-site/storage/original/ application/f55f354f730ce84d78cf81868 bccb59b.pdf.
34. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006;100:2129-36. (Pubitemid 44718399)
35. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, shortcourse levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60. (Pubitemid 37153652)
36. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2: S27-72. (Pubitemid 46290553)
37. SPILF. Prise en charge des infections des voies respiratoires basses de l'adulte immunocompétent. Texte court. 2006: http://www.infectiologie. com/site/medias/-documents/consensus/nf-respir-court-2006.pdf.
38. AFSSAPS. Antibiothérapie par voie générale en pratique courante dans les infections respiratoires hautes de l'adulteetde l'enfant. 2005: http://www.afssaps.fr/var/afssaps-site/storage/original/ application/e7545c16eaf2690369c724cf863f9c65.pdf.
39. Carlet J, Collignon P, Goldmann D, et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011;378:369-71.